Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Minnesota Equal Rights Amendment fails in acrimonious end to legislative session
Former Mormon reveals the wild list of rules she was forced to follow while living within ultra
The Montreal Canadiens have exercised the option on coach Martin St. Louis' contract
Mother who promised Taylor Swift tickets to her daughter to celebrate finishing her A
Seven sneaky clauses in estate agent contracts that can cost you dear
Lab chief faces sentencing in Michigan 12 years after fatal US meningitis outbreak
NHL has no appetite to expand playoffs beyond its 16
Gujarat crashes to 89 all out against Delhi, loses IPL game by 6 wickets at home
JoJo Siwa goes wild: Karma singer accused of getting drunk at Disney World after turning 21
NHL has no appetite to expand playoffs beyond its 16
Cannes 2024: Studio Ghibli takes a bow with an honorary Palme d'Or
How the US failed to stop a Cambodian monkey ‘smuggling conspiracy’ — Radio Free Asia